Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Change in Accured Expenses (2018 - 2025)

Historic Change in Accured Expenses for TransMedics (TMDX) over the last 8 years, with Q3 2025 value amounting to $13.1 million.

  • TransMedics' Change in Accured Expenses rose 16366.37% to $13.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.1 million, marking a year-over-year increase of 2305.08%. This contributed to the annual value of $7.9 million for FY2024, which is 4429.47% down from last year.
  • According to the latest figures from Q3 2025, TransMedics' Change in Accured Expenses is $13.1 million, which was up 16366.37% from $2.2 million recorded in Q2 2025.
  • TransMedics' Change in Accured Expenses' 5-year high stood at $13.1 million during Q3 2025, with a 5-year trough of -$4.6 million in Q1 2025.
  • Its 5-year average for Change in Accured Expenses is $2.2 million, with a median of $2.2 million in 2021.
  • As far as peak fluctuations go, TransMedics' Change in Accured Expenses surged by 8645000.0% in 2023, and later crashed by 937755.1% in 2025.
  • TransMedics' Change in Accured Expenses (Quarter) stood at $2.5 million in 2021, then skyrocketed by 36.76% to $3.4 million in 2022, then soared by 44.93% to $5.0 million in 2023, then plummeted by 53.45% to $2.3 million in 2024, then skyrocketed by 465.45% to $13.1 million in 2025.
  • Its last three reported values are $13.1 million in Q3 2025, $2.2 million for Q2 2025, and -$4.6 million during Q1 2025.